Phase II Study of Tazemetostat in Solid Tumors Harboring an ARID1A Mutation

Clinical trial NCT05023655 · TERMINATED

Trial details

NCT number: NCT05023655
Sponsor: Prisma Health-Upstate
Status: TERMINATED
Phase: Phase 2
Study type: INTERVENTIONAL

Solid Tumor ARID1A Gene Mutation

Start date: 2022-01-06
Primary completion: 2026-03-06
Enrollment: 20

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.